At a glance
ClinicalIndex Comparison RecordN/ANot Yet Recruiting· 200 target
Drug / intervention
Duvelisibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
(CHANT)A Prospective, Multicenter, Non-interventionistic Real-world Study of Duvelisib Capsules in the Treatment of Non-Hodgkin's Lymphoma (NHL).
In Brief
An observational study evaluating Duvelisib for Follicular Lymphoma and 5 related conditions. Not yet recruiting, targeting 200 participants.
Detailed Summary
This is a multicenter, non-interventional and prospective real-world study to evaluate the efficacy and safety of Duvelisib capsules in patients with non-Hodgkin's lymphoma.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsFollicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Richter Syndrome, Marginal Zone Lymphoma, Peripheral T Cell Lymphoma, Diffuse Large B Cell Lymphoma
Countries--
Collaborators--
Timeline
N/ANot Yet Recruiting
20242025202620272028
First PostedJun 2023
Enrollment StartOct 2023
TodayJul 2026
Primary CompletionNov 2027
First PostedJun 28, 2023
Enrollment StartOct 20, 2023
Primary CompletionNov 30, 2027
TodayJul 1, 2026
Enrollment to primary: 4.1 yearsPosted 3.0 years agoPrimary completion in 1.4 years
Interventions
Duvelisibdrug
This is a real-word. The treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients.